
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker

Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 5, 2026, 8:45 AM ET
DiaMedica Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Business Update November 13, 2026
U.S. listed: $DMACBiotech · Vascular and neurological careExecution and funding risks
DMAC Stock Hub: DiaMedica Therapeutics News, DM199 and Clinical Development
DiaMedica Therapeutics is developing DM199, a recombinant human KLK1 protein, to improve vascular function in acute ischemic stroke, preeclampsia and fetal growth restriction. ReMEDy2 reached 200 enrolled patients on October 22. Its Q1 2027 interim concerns sample size or futility, and the company stays blinded; final enrollment may range from 300 to 728 if it proceeds. Preliminary FGR findings are scheduled for November 24. Early pregnancy observations support further study, while the key questions remain clinical outcomes, maternal-fetal safety and financing. June liquidity was $43.5M and management expected planned operations to be funded through 2027.
Full research report · PDF
DiaMedica Therapeutics ($DMAC), research as of October 22, 2026
14 pages covering The report examines DM199, its proposed biology and the clinical evidence in vascular and neurological indications. It distinguishes trial milestones from treatment benefit, and follows manufacturing, regulatory execution, historical cash resources and the assumptions behind further funding needs. This is dated research; the hub follows later developments. For personal use only: redistribution prohibited.
Next company-announced financial event
November 13, 2026 · 8:00 a.m. ET · Q3 2026 results call
DiaMedica will release its third-quarter 2026 financial results after the market close on Thursday, November 12, and host a live conference call and webcast on Friday, November 13 at 8:00 a.m. ET to provide a business update and discuss the results; the webcast will remain available on the company website for 12 months. Company announcement →
Next clinical milestone: preliminary findings from the first two early-Phase 2 FGR cohorts are expected at the rescheduled November 24 event. The independent ReMEDy2 interim follows 90-day follow-up and is expected in Q1 2027; the company remains blinded. Primary source. Company-guided windows remain forecasts.
DMAC stock at a glance
Close · October 30, 2026
$9.25
Regular-session close; -2.84% versus $9.52 on October 29. USD.
Lead medicine
DM199
Rinvecalinase alfa; investigational recombinant KLK1
Stroke study
ReMEDy2 phase 2/3
Randomized, blinded, placebo-controlled
Interim threshold
200 enrolled
Milestone announced October 22, 2026
Independent interim
Q1 2027
Company expectation; sample-size or futility assessment
Next FGR event
November 24
2026; preliminary first- and second-cohort findings planned
June liquidity
$43.5M
Cash, equivalents and securities at June 30, 2026
H1 operating cash use
$17.2M
Six months ended June 30, 2026
Where DiaMedica Therapeutics stands now
DiaMedica Therapeutics is developing DM199, a recombinant human KLK1 protein, to improve vascular function in acute ischemic stroke, preeclampsia and fetal growth restriction. ReMEDy2 reached 200 enrolled patients on October 22. Its Q1 2027 interim concerns sample size or futility, and the company stays blinded; final enrollment may range from 300 to 728 if it proceeds. Preliminary FGR findings are scheduled for November 24. Early pregnancy observations support further study, while the key questions remain clinical outcomes, maternal-fetal safety and financing. June liquidity was $43.5M and management expected planned operations to be funded through 2027.
Execution and funding. The earlier stroke study lacked significant Day 90 secondary efficacy findings, and its favorable non-endovascular signal was post hoc. Pregnancy observations are small and open-label. Hypotension history, trial expansion, regulatory work, manufacturing dependence and further equity funding remain material risks.
The constructive case
DM199 addresses substantial unmet needs through a coherent vascular mechanism. Stroke enrollment has reached the interim threshold, while pregnancy studies provide another route to test clinical value. A persuasive controlled recovery benefit or reproducible maternal-fetal signal could support further development and financing flexibility.
The cautious case
The earlier stroke study lacked significant Day 90 secondary efficacy findings, and its favorable non-endovascular signal was post hoc. Pregnancy observations are small and open-label. Hypotension history, trial expansion, regulatory work, manufacturing dependence and further equity funding remain material risks.
Latest DiaMedica Therapeutics news
Nov 10, 2026
DiaMedica posts results for DM199 Phase 2 REDUX trial in chronic kidney disease
Results for the Phase 2 trial Multiple Doses of DM199 in Patients With Chronic Kidney Disease (REDUX), NCT04123613, were first posted on ClinicalTrials.gov on 2026-11-10. The trial enrolled 84 participants and its overall status is COMPLETED. The lead sponsor is DiaMedica Therapeutics Inc., and the listed condition is Kidney Diseases.
Nov 5, 2026
DiaMedica Therapeutics to report third quarter 2026 financial results and provide a business update
DiaMedica Therapeutics will report its third quarter 2026 financial results and provide a business update on November 13, 2026.
Oct 22, 2026
ReMEDy2 enrolls its 200th participant; independent interim analysis expected in Q1 2027
The stroke study reached its prespecified enrollment threshold. The independent board will assess sample-size re-estimation or futility after the first 200 participants complete 90-day follow-up. DiaMedica remains blinded and recruitment continues; if the study proceeds, final enrollment can range from 300 to 728.
Oct 19, 2026
FGR webinar moved to November 24 to include preliminary findings from two cohorts
The event replaces the October 23 date. The company plans to discuss safety, tolerability and early findings from the first and second FGR cohorts. Twelve participants were enrolled across the two cohorts; efficacy observations remain preliminary.
Sep 30, 2026
FGR webinar first scheduled for October 23
Historical scheduling announcement for October 23. The October 19 update moved the FGR event to November 24; the original date is superseded.
Aug 10, 2026
Q2 update reports $43.5M June liquidity and late-onset preeclampsia activity
Cash, equivalents and securities totaled $43.5M at June 30, with $17.2M of H1 operating cash use. Management expected funding through 2027. The open-label combined highest-dose preeclampsia cohorts included 15 participants and showed maternal blood-pressure reductions; larger studies are needed to establish broader maternal-fetal benefit.
DMAC stock catalysts and company milestones
- November 12–13, 2026 · Q3 2026 results — Results released after the market close on November 12; conference call and webcast on November 13 at 8:00 a.m. ET with a business update. Company-announced call · announcement
- November 24, 2026 — Preliminary findings from the first two early-Phase 2 FGR cohorts are expected at the rescheduled November 24 event. The independent ReMEDy2 interim follows 90-day follow-up and is expected in Q1 2027; the company remains blinded. Company guidance or announced event; timing qualifications retained
ReMEDy1 results: the foundation and its limitations
ReMEDy1 was a Phase 2, randomized, double-blind, placebo-controlled study conducted at 13 Australian sites. It randomized 92 patients within 24 hours of ischemic-stroke onset, with safety and tolerability as the primary objective. The publication appeared in the July 2026 issue of the International Journal of Stroke. Its principal contribution is direct human experience with DM199 in the disease of interest, together with exploratory observations that informed further development. Original ReMEDy1 publication
The key limitation is explicit: the study found no statistically significant differences in its secondary efficacy outcomes at Day 90. Post hoc analyses of patients who had not received endovascular treatment suggested a favorable tendency in excellent global outcomes. Those analyses help form a hypothesis for a selected population. They have less evidentiary weight than a prospectively specified positive efficacy endpoint in a sufficiently powered study.
DMAC earnings, cash, burn and runway
At June 30, 2026, DiaMedica reported $5.129 million in cash and equivalents and $38.375 million in marketable securities, totaling $43.504 million. The comparable December 2025 total was $59.890 million. Working capital was $37.721 million, and total current liabilities were $6.594 million. Those figures describe the quarter-end financial position; subsequent spending changes the amount available later in the year. June balance sheet
Operating activities used $17.196 million of cash in the first six months, compared with $14.747 million in the prior-year period. The 2026 figure averages approximately $2.866 million a month. This calculation describes historical cash use, not a contractual spending rate. Trial timing, payments to vendors and expansion of development can make future quarters differ materially.
Merlintrader Health Score · $DMAC
3.20out of 5
Assessed October 22, 2026; reviewed November 5, 2026, after the Q3 results date was announced, with the scores unchanged. Weighted calculation: 3.0×30% + 4.0×30% + 2.5×20% + 2.5×10% + 3.5×10% = 3.20. This describes financial and operational robustness over twelve to eighteen months, not an investment recommendation.
Red flags
- The earlier stroke study lacked significant Day 90 secondary efficacy findings, and its favorable non-endovascular signal was post hoc. Pregnancy observations are small and open-label. Hypotension history, trial expansion, regulatory work, manufacturing dependence and further equity funding remain material risks.
- Company forecasts depend on execution and may change.
- Financial balances retain their stated reporting date; later financing is separate.
- Investment involves possible loss of part or all of the capital.
DMAC Stock FAQ: DiaMedica Therapeutics Questions Answered
What is the next catalyst for DMAC stock, and when is the ReMEDy2 interim analysis?
DiaMedica’s next scheduled clinical update is its November 24, 2026 FGR webinar at 8:00 a.m. Eastern Time. Its October 22 announcement expects ReMEDy2 interim analysis in Q1 2027, after the first 200 participants complete 90-day follow-up. Enrollment reached that threshold, while recruitment continues and the company remains blinded. The independent board assesses sample-size re-estimation or futility; if the trial continues, the predetermined plan allows a final sample of 300–728 participants. October 19 webinar schedule. October 22 enrollment and interim-analysis plan.
Is DiaMedica’s DM199 FDA approved for stroke or pregnancy complications?
No. DiaMedica’s October 22, 2026 company description identifies DM199 as a clinical-development candidate for acute ischemic stroke, preeclampsia and fetal growth restriction. ReMEDy2 is a pivotal Phase 2/3 study, while the pregnancy programs have separate development paths. FDA discussions and ongoing studies are not evidence of approval for these uses. Current investigational programs.
How much cash does DiaMedica have, and what is its runway?
DiaMedica reported US$43.5 million in cash, equivalents and investments at June 30, 2026, with an August 10 outlook for planned operations through 2027. Cash and equivalents alone were US$5.129 million; first-half operating cash use was US$17.196 million. The funding estimate depends on the clinical plan, including how much work remains after interim review. August 10 liquidity and runway outlook. June cash components and cash flow.
Could DiaMedica issue more DMAC shares?
Yes. DiaMedica’s June-quarter filing describes an ATM program of up to US$100 million, with US$86.2 million remaining available as of June 3, 2026. It also lists options and share awards. That capacity permits potential additional issuance; it is not cash already received or a commitment to issue every available share. ATM terms, dated capacity and equity instruments.
When are DiaMedica Therapeutics’ next earnings?
DiaMedica will release its third-quarter 2026 financial results after the market close on Thursday, November 12, 2026, and host a conference call on Friday, November 13 at 8:00 a.m. ET to provide a business update and discuss the results, according to its November 5 announcement. Its latest quarterly results were released August 10 for the period ended June 30. November 5 announcement. The November 24 FGR webinar is a clinical event and should not be presented as an earnings release. Current company announcements. Latest quarterly results. Rescheduled clinical webinar.
What does DiaMedica Therapeutics do, and what is DM199?
DiaMedica develops medicines for vascular disorders, including acute ischemic stroke, preeclampsia and fetal growth restriction. Its October 22, 2026 description identifies DM199, or rinvecalinase alfa, as an experimental recombinant form of human tissue kallikrein-1. A shared vascular mechanism supports investigating these uses, but benefit and safety must be established in each population. Company and DM199 description.
Did DiaMedica’s ReMEDy1 trial prove DM199 works in stroke?
No. The ReMEDy1 paper, first published November 6, 2025, primarily assessed safety and tolerability in 92 participants. It found no statistically significant differences in secondary efficacy outcomes at Day 90. A favorable tendency among patients without endovascular therapy came from post hoc analysis; ReMEDy2 prospectively tests the next efficacy hypothesis. Original randomized ReMEDy1 study.
When will DiaMedica present fetal growth restriction results?
DiaMedica rescheduled its FGR webinar to November 24, 2026 at 8:00 a.m. Eastern Time, replacing October 23. The October 19 announcement says the event will include preliminary second-cohort results; its panel description refers to the first six treated participants. The small open-label study needs interpretation alongside baseline conditions, safety, delivery decisions and follow-up. October 19 revised webinar announcement.
Primary sources
- November 5, 2026 · DiaMedica to report Q3 2026 results after the close on November 12; call November 13 at 8:00 a.m. ET
- October 22, 2026 ReMEDy2 milestone
- October 19, 2026 FGR update
- Q2 financial and business update
- Form 10-Q for the quarter ended June 30, 2026
- ReMEDy2 registration
- Original ReMEDy1 publication
- Original pregnancy protocol
- Stroke rationale review
- Healthy-volunteer original study
- June 2026 FDA-feedback update
- June 2023 hold removal
- 2025 Form 10-K
- Approved TNKase label
- pregnancy-hypertension guidance
- October 22, 2026 — ReMEDy2 enrolls its 200th participant; independent interim analysis expected in Q1 2027
- October 19, 2026 — FGR webinar moved to November 24 to include preliminary findings from two cohorts
- September 30, 2026 — FGR webinar first scheduled for October 23
- August 10, 2026 — Q2 update reports $43.5M June liquidity and late-onset preeclampsia activity
- June 16, 2026 — FDA feedback outlines additional work for the U.S. pregnancy development pathway
- June 30, 2026 — Form 10-Q for the quarter ended June 30, 2026
Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent analysis and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $DMAC or any other security.
Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases and market-data providers, and are stated with their reference dates. Data can change without notice, and figures published before a results release become outdated the moment that release is issued. Merlintrader makes no representation that the information is complete or current at the time of reading. Readers should verify every figure against the primary source before acting on it.
Biotechnology companies face clinical, safety, regulatory, manufacturing, commercial and financing risks. Trials can fail, adverse effects can limit use, regulatory applications can be delayed or rejected, and an approved medicine may not achieve commercial expectations. Additional borrowing or equity issuance can increase obligations or dilute existing shareholders. Investors can lose part or all of their capital. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate.
Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.



